You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  2. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  4. Additive Manufacturing Sensor Fusion Technologies for Process Monitoring and Control.

    SBC: SENVOL LLC            Topic: DLA18A001

    The Department of Defense (DoD) has a demand for out-of-production parts to maintain mission readiness of various weapons platforms. Additive manufacturing (AM) is an exciting and promising manufacturing technique that can make out-of-production parts and holds the potential to solve supply chain issues, such as high costs (i.e. for low-volume parts) and sole sourcing risks. The ability of AM to s ...

    STTR Phase I 2018 Department of DefenseDefense Logistics Agency
  5. Smart Baseplate for Additive Manufacturing

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: DLA18A001

    Additive manufacturing (AM) has rapidly evolved into a valuable technique for making parts which, at times, cannot be fabricated through conventional machining methods.One challenge in the area of AM is the lack of real-time feedback on the fabrication process and the quality of the part being made.This is especially critical given the relatively long periods of time that complex parts can require ...

    STTR Phase I 2018 Department of DefenseDefense Logistics Agency
  6. STTR Phase I: Manganese Oxide-Carbon Nanosheet Anodes for Extreme High Power Lithium Ion Batteries

    SBC: EnerMat Technologies, Inc.            Topic: CT

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) project is the advancement of improved lithium ion batteries. The project will evaluate new battery chemistry enabling more rapid charging rates then currently available in the worldwide energy storage marketplace. Such high power density batteries would cater to a major emerging battery segment where current ...

    STTR Phase I 2018 National Science Foundation
  7. STTR Phase I: Development of a Process to Extend the Shelf Life of Fruits and Vegetables at Ambient Temperature

    SBC: Natural Cuts, Inc            Topic: CT

    The broader impact/commercial potential of this STTR Phase I project is a sustainable fruit and vegetable processing technology utilizing a new, low temperature technique that can extend the shelf life of pre-cut fruits and vegetables by months without using preservatives, chemicals, freezing, or refrigeration. The technology would enable: all-natural, shelf stable fruit and vegetable products tha ...

    STTR Phase I 2018 National Science Foundation
  8. STTR Phase I: Protecting Livestock from Airborne Disease Transmission Using Non-thermal Plasma Airstream Disinfection

    SBC: Taza Aya LLC            Topic: CT

    The broader impact/commercial potential of this STTR project stems from the costs to U.S. food producers of outbreaks of animal diseases. Producers of poultry, pork, and other food proteins lose more than $1B each year to infectious diseases, including some that are transmitted through the air. For diseases having an airborne transmission route, protective technologies that are available are few a ...

    STTR Phase I 2018 National Science Foundation
  9. STTR Phase I: A Fully-Digital Transceiver Design for mmWave Communications

    SBC: PI Radio, Inc            Topic: EW

    The broader impact/commercial potential of this project covers a myriad of domains including wireless health-care, remote education, supply-chain management, public safety, anti-poverty initiatives, market-places, and entertainment. However, a more immediate work product from this effort is a powerful fully-digital mmWave software defined radio (SDR) platform that will be made available to academi ...

    STTR Phase I 2018 National Science Foundation
  10. Functionalized, Therapeutic-Loaded Liposomes for the Acute Treatment of TBI

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: DHA18A001

    Traumatic brain injury is a common problem in both the military and civilian communities, but current treatment protocols are focused on managing symptoms and fail to prevent significant long-term repercussions. In the proposed program, Luna will demonstrate the feasibility of a liposome-based therapeutic delivery system capable of delivering hydrophilic and hydrophobic therapeutics to the traumat ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government